News | January 29, 2023
Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
The company will engage with the agency to resolve the import alert at the earliest.
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Granules now have a total of 53 ANDA approvals from USFDA
Subscribe To Our Newsletter & Stay Updated
